Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer

Targeted therapy has brought revolutionary breakthroughs for radioiodine-refractory differentiated thyroid cancer. New targeted drugs have prolonged the survival of patients with advanced differentiated thyroid cancer. Multiple tyrosine kinase inhibitors, represented by sorafenib and lenvatinib, hav...

Full description

Bibliographic Details
Main Authors: TENG Lisong, XU Zehang, WANG Weibin
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2023-05-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
radioiodine-refractory differentiated thyroid cancer
targeted therapy
tyrosine kinase inhibitor
Online Access:http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0009

Internet

http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0009

Similar Items